Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)
CUSIP: 761330109
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 104,661,494
- Total 13F shares
- 86,100
- Share change
- -80,984,685
- Total reported value
- $425,000
- Price per share
- $4.94
- Number of holders
- 1
- Value change
- -$246,196,147
- Number of sells
- 164
Quarterly Holders Quick Answers
What is CUSIP 761330109?
CUSIP 761330109 identifies RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 761330109:
Top shareholders of RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Teoxane SA |
13D/G
|
— |
6.2%
|
6,550,800
|
$32,335,404 | $0 | 30 Jan 2025 | |
| BlackRock, Inc. |
13F
|
Company |
8.2%
|
8,597,418
|
$26,136,151 | — | 31 Dec 2024 | |
| FRANKLIN RESOURCES INC |
13D/G
13F
|
Company |
4.6%
|
4,784,658
|
$23,617,550 | $0 | 30 Sep 2024 | |
| Beryl Capital Management LLC |
13F
|
Company |
5.7%
|
5,935,009
|
$18,042,427 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.4%
|
5,625,091
|
$17,100,277 | — | 31 Dec 2024 | |
| ODDO BHF ASSET MANAGEMENT SAS |
13F
|
Company |
4.9%
|
5,100,000
|
$15,504,000 | — | 31 Dec 2024 | |
| FIL Ltd |
13F
|
Company |
4%
|
4,196,095
|
$12,756,129 | — | 31 Dec 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
3.3%
|
3,497,112
|
$10,631,220 | — | 31 Dec 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
3%
|
3,164,943
|
$9,621,427 | — | 31 Dec 2024 | |
| Palo Alto Investors LP |
13D/G
|
Patrick Lee, MD |
1.5%
|
1,611,787
|
$7,955,942 | $0 | 30 Sep 2024 | |
| Magnetar Financial LLC |
13F
|
Company |
2.4%
|
2,556,345
|
$7,771,289 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.3%
|
2,439,140
|
$7,414,986 | — | 31 Dec 2024 | |
| ALPINE ASSOCIATES MANAGEMENT INC. |
13F
|
Company |
2.2%
|
2,349,966
|
$7,143,898 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
2,297,582
|
$6,986,220 | — | 31 Dec 2024 | |
| GLAZER CAPITAL, LLC |
13F
|
Company |
1.9%
|
1,950,000
|
$5,928,000 | — | 31 Dec 2024 | |
| Newtyn Management, LLC |
13F
|
Company |
1.7%
|
1,810,000
|
$5,502,400 | — | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.6%
|
1,653,689
|
$5,027,215 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.5%
|
1,551,372
|
$4,716,171 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
1.4%
|
1,483,040
|
$4,508,442 | — | 31 Dec 2024 | |
| AQR Arbitrage LLC |
13F
|
Company |
1.4%
|
1,413,103
|
$4,295,833 | — | 31 Dec 2024 | |
| Aubrey Rankin |
3/4/5
|
Director |
—
class O/S missing
|
570,004
|
$4,257,930 | — | 15 Mar 2022 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.3%
|
1,367,343
|
$4,156,723 | — | 31 Dec 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1.3%
|
1,328,525
|
$4,038,716 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.2%
|
1,298,822
|
$3,948,419 | — | 31 Dec 2024 | |
| GABELLI FUNDS LLC |
13F
|
Company |
1.2%
|
1,262,487
|
$3,837,960 | — | 31 Dec 2024 | |
| CIBRA Capital Ltd |
13F
|
Company |
1.1%
|
1,139,979
|
$3,465,536 | — | 31 Dec 2024 | |
| GABELLI & Co INVESTMENT ADVISERS, INC. |
13F
|
Company |
1%
|
1,058,500
|
$3,217,840 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.95%
|
991,043
|
$3,012,771 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.85%
|
893,686
|
$2,716,806 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.78%
|
812,927
|
$2,471,298 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.76%
|
797,299
|
$2,423,789 | — | 31 Dec 2024 | |
| WATER ISLAND CAPITAL LLC |
13F
|
Company |
0.69%
|
722,234
|
$2,195,592 | — | 31 Dec 2024 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.65%
|
678,541
|
$2,062,765 | — | 31 Dec 2024 | |
| Slotnik Capital, LLC |
13F
|
Company |
0.64%
|
671,607
|
$2,041,685 | — | 31 Dec 2024 | |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC |
13F
|
Company |
0.53%
|
551,224
|
$1,675,721 | — | 31 Dec 2024 | |
| FNY Investment Advisers, LLC |
13F
|
Company |
0.46%
|
477,823
|
$1,452,000 | — | 31 Dec 2024 | |
| Essex Woodlands Management, Inc. |
13F
|
Company |
0.44%
|
457,085
|
$1,389,538 | — | 31 Dec 2024 | |
| Man Group plc |
13F
|
Company |
0.42%
|
443,544
|
$1,348,374 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.4%
|
423,189
|
$1,286,495 | — | 31 Dec 2024 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.4%
|
414,310
|
$1,259,502 | — | 31 Dec 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.39%
|
411,523
|
$1,251,030 | — | 31 Dec 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.38%
|
402,691
|
$1,224,181 | — | 31 Dec 2024 | |
| National Philanthropic Trust |
13F
|
Company |
0.33%
|
350,000
|
$1,064,000 | — | 31 Dec 2024 | |
| Vazirani Asset Management LLC |
13F
|
Company |
0.33%
|
350,000
|
$1,064,000 | — | 31 Dec 2024 | |
| LMR Partners LLP |
13F
|
Company |
0.33%
|
347,207
|
$1,055,509 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.29%
|
307,764
|
$935,603 | — | 31 Dec 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.29%
|
303,073
|
$921,342 | — | 31 Dec 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.29%
|
299,039
|
$909,079 | — | 31 Dec 2024 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.28%
|
297,458
|
$904,000 | — | 31 Dec 2024 | |
| Abhay Joshi |
3/4/5
|
COO, President of R&D |
—
class O/S missing
|
120,708
|
$901,689 | — | 15 Mar 2022 |
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2025
As of 31 Mar 2025,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
86,100 shares.
The largest 1 holders included
DekaBank Deutsche Girozentrale.
This page lists
1
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
169
Q1 2025 holders
1
Holder diff
-168
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.